Why the study?
Do oral antidiabetic agents (glipizide or metformin) improve cardiovascular surrogate markers in non-diabetic African American patients with insulin resistance?
Do oral antidiabetic agents (glipizide or metformin) improve cardiovascular surrogate markers in non-diabetic African American patients with insulin resistance?
In non-diabetic African Americans with insulin resistance, treatment with glipizide or metformin paradoxically increased aortic pulse wave velocity, suggesting a decrease in aortic elasticity.
Answers are grounded in this paper and cite their sources.
Both agents increased aortic stiffness; challenges presumed CV surrogate benefits of these agents in non-diabetic insulin-resistant African Americans.
OBJECTIVE: To study the long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance. PATIENTS: 181 African American subjects with insulin resistance and normal glucose tolerance test were randomised to receive glipizide 5 mg/day (n = 25), metformin 500 mg/day (n = 59), or placebo (n = 97) for 24 months. Insulin sensitivity, glucose tolerance, lipid profile, left ventricular mass (echocardiography), aortic distensibility (echocardiography, blood pressure), aortic pulse wave velocity (PWV, carotid to femoral artery, Doppler) were measured at baseline and at 12 and 24 months after randomisation. RESULTS: A significant increase in PWV was observed in both glipizide (mean (SEM) change at 24 months 2.8 (2.7) m/s, p = 0.012) and metformin (2.2 (0.7) m/s, p = 0.01) groups during the follow up period. In contrast, PWV remained unchanged in the placebo group. The increase in PWV in the treatment groups was significant compared with placebo (analysis of variance p < 0.05). Other cardiovascular or metabolic variables did not change significantly compared with placebo during follow up. CONCLUSIONS: The observed increase in PWV is consistent with a decrease in the elastic properties of the aorta. The use of oral antidiabetic agents for the prevention of cardiovascular complications in non-diabetic African Americans with insulin resistance needs to be critically evaluated.
No takes yet. Share an insight, caveat, or question.
Dimitrios Stakos (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: